Easy ways to save patients lives: How to prevent, recognize and deter prescription drug abuse.
|
|
- Clifford Hampton
- 5 years ago
- Views:
Transcription
1 Easy ways to save patients lives: How to prevent, recognize and deter prescription drug abuse. Chris Stock, PharmD, BCPP Professor (Adjunct), U of U Clinical Pharmacy Specialist, VAMC 1
2 Attending the presentation will enhance pharmacists' knowledge of available information regarding pain medication abuse and possible opportunities for intervention and patient and prescriber education. Attendees will be able to: 1) State the statistics of pain medication abuse occurring in the United States, among various demographic groups. 2) Specify the impact of the under treatment of pain and inadequate pain relief. 3) Identify a number of ways to deter pain medication abuse in the homes of families in the United States. 4) Identify the dangers associated with non medical use of prescription pain medications. 5) Identify means to reduce the risk of prescription opioid abuse At the end of the presentation you will be able to correctly answer these questions: 1) According to Utah regulations, pharmacists can authorize a pharmacy technician to access the Utah Controlled Substance Database. True or False 2) According to Utah regulations, prescribers can authorize a non-medical clinic employee to access the Utah Controlled Substance Database. True or False 3) According to the National Survey on Drug Use and Health 2011 results, which group is most likely to engage in the non-medical use of opioid prescription medications? years old years old years old 4. Over 65 years old 4) The National Associations of Boards of Pharmacy has promoted which of the following methods to deter inappropriate prescribing as well as abuse of controlled substances. 1. National database of doctor shoppers 2. National database of pill mill doctors 3. Searchable national database of controlled substance prescriptions 4. National hot line for reporting pharmacy robberies 2
3 INCB* 2012 Annual Report North America IS: THE BIGGEST illicit drug market in the world. HIGHEST drug-related mortality rate. 1 in every 20 deaths in North America (15-64age) Overdose deaths HIV/AIDS Trauma-related deaths including MVAs International Narcotics Control Board of UN Economic Costs of Drug Abuse Department of Justice 2011 $193 Billions $11,416,232 Crime Productivity Health $68,403,082 $113,277,616 3
4 Past Year Illicit Drug Use among Persons Aged 12 or Older: 2011 Marijuana 29,739,000 Rx drugs 14,657,000 Opioids 11,143,000 Hallucinogens 4,069,000 Cocaine 3,857,000 Inhalants 1,861,000 Heroin 620,000-5,000,000 10,000,000 15,000,000 20,000,000 25,000,000 30,000,000 35,000,000 Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, Costs of Abuse of Prescription Drugs 2006 $53 Billions $2.20 $0.94 $8.20 Productivity Criminal Justice Treatment Medical $42.00 Hansen, et al. Economic Costs Clin J Pain 2011;27:
5 Hydromorph 2% Fentanyl 0% Drug's Costs $53 Billions Meperidine 4% Morphine 5% Other 4% OxyContin 14% Codeine 8% Oxycod 11% Methadone 12% Hydrocod 24% Darvon 16% Hansen, et al. Economic Costs Clin J Pain 2011;27: Who is abusing, misusing, dying? 5
6 Age Groups: Non-medical Pain Reliever Use: ,500,000 6,600,000 3,600, to to Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, Nonmedical Use of Pain Relievers among Persons Aged 12 or Older SAMHSA 2012 NSDUH Survey Report 6
7 What are the consequences? Addiction Bridging (may be related to addiction or unmanaged pain) Overdose Addiction Chronic disease of the portions of the brain that control Reward Motivation Memory Root causes can be traced back to Genetics Environment Resiliency Culture ASAM: Public Policy Statement: Definition of Addiction (Long Version)
8 Spectrum of use: Age 12 and over 2,000,000 Abuser/Addict Users 11,000,000 Abstainers 241,000,000 Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, Past Year Dependence Criteria among Persons Aged 12 or Older Millions Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration,
9 Past Year Received Treatment for Drug Dependence: 12 or Older: ,000,000 4,500,000 4,000,000 3,500,000 3,000,000 2,500,000 Have Abuse Dependence Treatment gap 2,000,000 1,500,000 Received Treatment 1,000, ,000 Substance Abuse -and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, Total NSDUH Dependent Series H-44, HHS Publication No. (SMA) Total Treated Rockville, MD: Substance Abuse and Mental Health Services Administration, BRIDGING Using what ever is available on the street to temporarily substitute for or replace the drugs you have become addicted to. Oxycodone Hydrocodone Suboxone Methadone Tramadol Above plus Seroquel, gabapentin, benzodiazepine, etc. 9
10 Why do we care Sources: National Vital Statistics System. Mortality data. Available at 10
11 Rate/100K population of unintentional drug overdose deaths OxyContin 2001 TJC pain tx a standard 2004 FSMB Mandates pain tx 1986 <1% addiction risk debate 1996 Pain Soc: 5 th Vital Sign 1998 FSMB Loosens Opioid rx ing 2007 Purdue guilty re: Oxy fraud One death every 19 minutes. Increase has been driven by increased use of opioid analgesics. Jones, Mack, Paulozzi (CDC). JAMA, February 20,
12 Gender: 38, 329 Overdose Deaths ,323 Male Female 23,006 Mack, Jones, Paulozzi (CDC). MMWR, July 2, 2013 Compton, Volkow, Throckmorton (NIDA/FDA) Ann Intern Med. 2013;158:65-66 Jones, Mack, Paulozzi (CDC). JAMA, February 20,
13 Jones, Mack, Paulozzi (CDC). JAMA, February 20, 2013 WHY? Jones, Mack, Paulozzi (CDC). JAMA, February 20,
14 Sources of drugs: 4.8% 6.7% 4.4% 0.4% 11.4% 55.0% Friend/relative - Free MD Friend/relative - $ Other Friend/relative - Stole Dealer Internet 17.3% Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, Utah DOH
15 15
16 Tramadol It IS an OPIOID! It is a CS in UTAH! 16
17 Who Is At Risk? Adverse Selection Those individuals who are most likely to receive chronic opioid therapy are also those who are most likely to develop opioid abuse/dependence. Histories of sexual, physical abuse History/risk of other substance abuse Current/history of other psychiatric illness This patient is hard to manage!»mark Sullivan, MD, PhD, U Wash 17
18 Percentage of patients and prescription drug overdoses, by risk group CDC January 13, 2012 / 61(01); % 10 % 40 % 80 % 40 % 20 % RISK GROUP: 10% high doses ( 100 mg morphine per day) by a single doc 40% of overdoses 10% high doses ( 100 mg per day) by MULTIPLE docs 40% of overdoses. 80% low doses (<100 mg per day) by a single doc 20% of overdoses. Drug overdose rate for women Mack, Jones, Paulozzi (CDC MMWR July 2,
19 Veterans Are At Risk Higher rates among VA patients Other risks Opioid dose > 100mg morphine equiv. per day Known alcohol and cocaine abuse Combo with benzos Chronic (> 90 days) opioids Sleep apnea 19
20 Where are overdoses occurring CDC 2008 data Who Is At Risk? Veterans Women Prescribed high dose opioids From: Utah, Nevada, Colorado, Idaho, Oregon, Washington, Arizona, New Mexico, Alaska, Oklahoma, Lousiana, Florida, etc. History/vulnerability for substance abuse Current or history of psychiatric illness 20
21 What about pain? Pain Sensations and Relievers 21
22 How are we doing treating pain? Perception of how well pain is managed is strongly tied to patients overall satisfaction with hospital experience From: What are we doing about abuse and overdoses? 22
23 FDA Actions to date: Encouraged pharma to develop data on the comparability of various formulations of naloxone REMS for opioids focused on prescriber and patient education Reschedule hydrocodone (Lortab/Vicodin) Schedule II Approval of Abuse Deterrent Formulations Possible Abuse Deterrents Mechanism Purpose Physical modification of tablet Prevent crushing, chewing Chemical Add antagonist Add aversive agent Depot formulation Pro-drug Prevent extracting Blockthe effect or get sick if misused Get sick if misused Assure medication is in body Becomes active only in bloodstream 23
24 Unintended Consequence of Changing OxyContin Formulation Cicero, et al. NEJM July 12, 2012 OxyContin Reformulated Medical provider responsibilities Prescribe wisely» Use Prescription Drug Monitoring Programs Follow prescribing guidelines» State s» Federation of State Medical Boards new guidelines Laboratory toxicology analysis 24
25 Help MDs interpret tests by understanding Opioid Metabolism Buprenorphine ----> Norbuprenorphine Robert Swotinsky MD, 11/2006 MRO Question board Education June 28, 2013 Emphasizes Balance Between Appropriate Pain Management and Prevention of Prescription Drug Abuse & Diversion CHICAGO The American Medical Association (AMA) is now offering an updated pain management education program to provide physicians with up-to-date information on the assessment and management of pain. Funding for this update was made possible by support from the Prescribers' Clinical Support System for Opioid Therapies, a group of health care organizations led by the American Academy of Addiction Psychiatry that received grant funding from the Substance Abuse and Mental Health Services Administration. 25
26 UT: State Board of Pharmacy, PDMP database Controlled Substance Database-CSD Database providing data on the dispensing of Schedule II-V drugs by all retail, institutional, and outpatient hospital pharmacies, and instate/out-of-state mail order pharmacies records Does not contain information from prescriptions filled at federal facilities, pharmacies licensed by other states, or controlled substances administered in an inpatient setting Monthly CSD training available for two hours of continuing education towards license renewal requirements To register for the database visit Who uses/accesses CSD? MD s > 80% Pharmacists < 30 % 26
27 Actions to take when CSD accessed? Refuse to prescribe? Contact pharmacy? Refuse to fill? Contact prescriber? Reporting????? Can you identify legitimate medical use from CSD? You can see: Multiple rx s Multiple prescribers Multiple pharmacies Overlapping dates Traveling to get prescriptions filled 27
28 You cannot see: This weeks prescriptions (yet) VA, HILL AFB or other federal data! 50,000 veterans, s of prescriptions Rx s from other states (yet) Marijuana, cocaine, non-prescribed benzos INTENT (i.e. is there a legitimate medical purpose?) Results of any urine drug testing Are they taking it or diverting it? Can you fill a prescription? What constitutes knowing the prescription is being not being used for legitimate medical purpose? Is it going to be diverted Is it going to be intentionally abused, i.e. injected, snorted, smoked, chewed to get high VS Misused to treat unmanaged pain 28
29 UTAH Legislative Actions 1995 Utah Controlled Substance Database 2007 H.B. 137 to created Prescription Pain Medication Program 2009 Utah Clinical Guidelines on Prescribing Opioids is released H.B. 28 Utah Controlled Substance Database registration mandatory 2011 S.B. 61 Four hours prescribing classes required each licensing period 29
30 Screening, Brief Intervention, and Referral to Treatment (SBIRT) Comprehensive, integrated, public health approach in primary care centers, hospital emergency rooms, trauma centers, and other community settings to prevent problems earlier. SBIRT in a nutshell ASK about tobacco, alcohol and drug use ASSESS by brief screen if positive: ADVISE of need to change, non-judgemental, personal message (meaningful to them) ASSIST by motivational interviewing to facilitate change if resistant or referral for specialty care if accept or need ARRANGE FOLLOW-UP to support, measure and reinforce change 30
31 Opioid Risk Tool (ORT) Predicts aberrant behavior Based on Gender, Age, Personal and Family substance abuse history, Sexual abuse history, Psychiatric conditions present Total Score Risk Category Low Risk 0 3 Moderate Risk 4 7 High Risk > 8 Reference: Webster LR. Predicting aberrant behaviors in opioidtreated patients 31
32 Screener and Opioid Assessment (SOAPP) Never, sometimes, often, always scale 24 questions Only 14 are scored and predict aberrant behavior 2, 7, 10, 11, 12, 13, 15, 17, 18, 19, 20, 22, 23, 24 A score of 7 or higher is considered positive risk CAGE, CAGE AID 4 Questions about alcohol and/or drug use Felt need to Cut down use? Feel Angry/annoyed when your use is mentioned? Feel Guilty or forgo responsibilities when you use? Need an Eye-opener or need to use to get your day or activities started or steady nerves? 1 positive = 79% sensitive 77% specific 2 positive = 70% sensitive 85% specific If positive, further assessment or referral should be made. 32
33 Drug Abuse Screening Tool (DAST) 28 Questions Self-administered Score 6-11 = further evaluation Score 12 or higher = refer for treatment Substance Abuse Subtle Screening Inventory (SASSI) 67 item self-administered questionnaire PROPRIETARY must pay to use _SASSI.pdf 33
34 Adult Substance Use Survey (ASUS) The ASUS-R is part of the SAM Computer Software Application UT: Use only as directed Program designed for medical professionals as well as the general public Focuses on abuse, safe use, safe storage, and safe disposal of prescription medications Offers a support forum to medical professionals 34
35 National: AWARERxE; The Medicine Abuse Project National website focused on providing information on prescription medication abuse to parents and grandparents, health care providers, communities and law enforcement, and educators Shares personal stories of individuals affected by prescription drug abuse Provides recent news stories related to prescription drug abuse Educate to Prevent Overdoses 35
36 Signs of Opioid Overdose Check: Appears sleepy, hard to arouse Listen: Shallow breathing, snoring, raspy or gurgling sounds Look: Bluish or grayish lips, fingernails, skin Touch: Clammy/sweaty skin 36
37 Where is naloxone distribution occurring? At the end of the presentation you will be able to correctly answer these questions: 1) According to Utah regulations, pharmacists can authorize a pharmacy technician to access the Utah Controlled Substance Database. True or False 2) According to Utah regulations, prescribers can authorize a non-medical clinic employee to access the Utah Controlled Substance Database. True or False 3) According to the National Survey on Drug Use and Health 2011 results, which group is most likely to engage in the non-medical use of opioid prescription medications? years old years old years old 4. Over 65 years old 4) The National Associations of Boards of Pharmacy has promoted which of the following methods to deter inappropriate prescribing as well as abuse of controlled substances. 1. National database of doctor shoppers 2. National database of pill mill doctors 3. Searchable national database of controlled substance prescriptions 4. National hot line for reporting pharmacy robberies 37
38 38
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx
Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services
More informationPRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE
PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE September 20, 2013 Association of State and Territorial Health Officials Annual Meeting R. Gil Kerlikowske Director of National Drug Control Policy National
More informationArticle #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic
Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationChallenges in Conducting Postmarketing Abuse Investigations
Challenges in Conducting Postmarketing Abuse Investigations Paul Coplan, ScD, MBA Risk Management & Epidemiology Purdue Pharma, L.P. ADF Guidance Meeting Washington DC, October 1, 2013 1 That which we
More informationPrescription Drug Abuse Task Force Rx Report Card
San Diego County Prescription Drug Abuse Task Force 2016 Rx Report Card October 2016 Key Measures of Prescription Drug and Heroin Problems in San Diego County. Visit www.sandiegorxabusetaskforce.org for
More informationOpioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities
1 National Academy of Medicine Session 4 Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center
More informationPrescription Drug Abuse National Perspective
Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationEffect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids
Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids Richard C. Dart, MD, PhD Executive Director, RADARS System Professor, University of Colorado Competing
More informationMichael M. Miller, MD, FASAM, FAPA
Michael M. Miller, MD, FASAM, FAPA mmiller@rogershospital.org Medical Director, Herrington Recovery Center (HRC) Rogers Memorial Hospital Oconomowoc, Wisconsin Vice Speaker Wisconsin Medical Society Clinical
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationThe Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country
Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationAbuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions
Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions Eric Lavonas, MD, FACEP, FACMT, FAACT Associate Director, Rocky Mountain Poison & Drug Center Denver
More informationPrescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach. For Pfizer Use Only
Prescription Opioid Abuse: Abuse-Deterrent Opioids as Part of a Multipronged Approach Table of Contents Chronic Pain and Prescription Opioids Source of Prescription Opioids and Patient Risk Assessment
More informationOpioid Deaths Quadruple Since 1999
THE COUNCIL OF STATE GOVERNMENTS CAPITOL RESEARCH AUGUST 2017 HEALTH POLICY Opioid Deaths Quadruple Since 1999 Since 1999, the number of overdose deaths involving opioids (including prescription opioids
More informationScope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.
Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond David Anisman, MD Medical Director, Farmington Health Center (Primary Care) Associate Medical Director, Community
More informationStrategies to Manage The Opioid Crisis
Strategies to Manage The Opioid Crisis Matt Feehery, LCDC Senior Vice President & CEO PaRC (Prevention & Recovery Center) Behavioral Health Services February 1, 2018 A Pill for Your Pain But my doctor
More informationBest Practices for Prescribing Controlled Substances
Best Practices for Prescribing Controlled Substances Dr. Merrill Norton Pharm.D., D.Ph, ICCDP-D Clinical Associate Professor University of Georgia College of Pharmacy mernort@uga.edu Georgia Composite
More informationValue of Abuse-Deterrent Opioids. For your personal use. Not for further distribution.
Value of Abuse-Deterrent Opioids HHS Data Show that Prescription Opioid Abuse Continues To Be a Serious Public Health Issue At least half of all opioid overdose deaths in the United States (US) involve
More informationThe Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010
The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationCategory 4 Can we prove that ADF opioids really are?
Human Abuse Liability & Abuse-Deterrent Formulations Category 4 Can we prove that ADF opioids really are? March 7, 2016 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Executive
More informationPreventing Prescription Drug Abuse
Preventing Prescription Drug Abuse Nicholas Reuter Center for Substance Abuse Treatment Substance Abuse Mental Health Services Administration U.S. Department of Health & Human Services Harold Rogers Prescription
More informationNYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.
NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationEpidemiologic Data on Opioid Use: Changing Problems
Epidemiologic Data on Opioid Use: Changing Problems 1 Goals 1 To bridge the pain world and addiction world 1. Pain and pain treatment a. Chronic pain affects an estimated 100 million Americans (1/3 of
More informationPain and Addiction Challenges in 2013
Pain and Addiction Challenges in 2013 12JUN2013 1200 EDT IntNSA Webinar Series Funding for this webinar was made possible (in part) by (1H79T1022022) from SAMHSA. The views expressed in written webinar
More informationAddressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain
Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain Ajay D. Wasan, MD, MSc Professor of Anesthesiology and Psychiatry Vice Chair for Pain Medicine, Department of Anesthesiology University
More informationThe Prescription Drug Overdose Epidemic
The Prescription Drug Overdose Epidemic Rita Noonan, PhD National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and Control Division
More informationThe Challenge of Treating Pain
FDA Charge to the Committee: FDA Opioid Action Plan and Incorporating the Broader Public Health Impact into the Formal Risk-Benefit Assessment for Opioids Robert M. Califf, MD Commissioner of Food and
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationApril 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)
New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director
More informationThe Population is Abusing Drugs, but are Drugs Abusing Insurance?
Image licensed from Shutterstock The Population is Abusing Drugs, but are Drugs Abusing Insurance? 01/30/2018 Gina C. Guzman, MD, DBIM, FALU, FLMI, VP and Chief Medical Director Tim Morant, FSA, MAAA,
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationThere are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014
Maintaining Patient Safety When Chronic Opioid Therapy Is Prescribed P. David Pacheco, Ph.C, PA-C, CAAAPM Pain Medication Management Specialist Southwest Interventional Pain Specialists, PC 4700 Jefferson
More informationTable of Contents Interim Report of the OxyContin Task Force, Newfoundland & Labrador, January 30, 2004
OXYCONTIN TASK FORCE INTERIM REPORT January 30, 2004 Submitted to Hon. Elizabeth Marshall, Minister of Health & Community Services, Government of Newfoundland and Labrador Table of Contents INTRODUCTION
More informationOpioid Epidemic as it Relates to Counties
89 TH ANNUAL WEST TEXAS COUNTY JUDGES AND COMMISSIONERS ASSOCIATION CONFERENCE Wednesday, April 25, 2018 11:05 11:55 a.m. Opioid Epidemic as it Relates to Counties Ms. Jessica Cance Agency Analytics Unit
More informationNorth Carolina, like the rest of the nation, has been experiencing
INVITED COMMENTARY The North Carolina Controlled Substances Reporting System: A Valuable Tool for Combating Prescription Drug Misuse William D. Bronson Prescription drug misuse is a growing problem that
More informationPrescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder
Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM Preventative Education: Substance Use Disorder Misuse of prescription pain relievers is, after marijuana use, the second most common form of
More informationPotential Solutions to Epidemic Substance Abuse in US and Europe
Potential Solutions to Epidemic Substance Abuse in US and Europe Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center, Denver Health 1 Professor, University of Colorado School of Medicine
More informationEmergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States,
Morbidity and Mortality Weekly Report (MMWR) Emergency Department Visits Involving Nonmedical Use of Selected Prescription Drugs --- United States, 2004--2008 Weekly June 18, 2010 / 59(23);705-709 Rates
More informationLisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR
Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR 1 1. Skin disorders, including cysts, acne, and dermatitis. 2. Joint disorders, including osteoarthritis. 3. Back problems. Source: Mayo
More informationHHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder
HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding
More informationOpioids drive continued increase in drug overdose deaths
CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th
More informationProject Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data
Project Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data Presented to Bureau of Justice Assistance Harold Rogers Prescription
More informationOpioid Use and Other Trends
Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current
More informationOPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN
OPIOIDS: THE GOOD, THE BAD, AND EVERYTHING IN-BETWEEN ANTOINETTE BROWN, RPH LAUREL RAMER, 2019 PHARMD CANDIDATE 2018 WYOMING CONFERENCE ON AGING LARAMIE, WY OCTOBER 3, 2018 OBJECTIVES 1. Understand the
More informationOpioid Use: Current Challenges & Clinical Advancements
Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize
More informationVirtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4:
Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: 279-283. POLICY FORUM OxyContin, the FDA, and Drug Control Gary M. Reisfield, MD One percent of people will
More informationOHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS
OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements found in the opium poppy plant. These drugs are
More informationPrescription Abuse: Cause, Consequence and Control
Prescription Abuse: Cause, Consequence and Control Glen R. Hanson, Ph.D., D.D.S. Professor in Pharmacology, University of Utah Director of the Utah Addiction Center, University of Utah Senior Advisor,
More informationMEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER
MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER JOHN E LOPES Jr., DHSC, PA-C Associate Professor, Physician Assistant Program Central Michigan University and Project Director Medication-assisted
More informationSubstance Use Trends in the Military, Veteran and Family Population
Substance Use Trends in the Military, Veteran and Family Population Prepared by: Shana Malone Arizona Criminal Justice Commission Statistical Analysis Center National Illicit Drug Use 1 in 10 individuals
More informationUnderstanding the US Opioid Analgesic Market
Understanding the US Opioid Analgesic Market Key Trends & Market Snapshot December 2017 Purdue Pharma L.P. provided funding and content review for this report. Avalere Health maintained full editorial
More informationChairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield and
United States House of Representatives Committee on Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade Hearing on Chairwoman Bono Mack, Vice-Chairwoman Blackburn, Ranking Member Butterfield
More informationEnd the Epidemic. Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN
End the Epidemic Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN 2018 2021 Miami-Dade County along with the State of Florida and the Nation are dramatically impacted by an Opioid Epidemic
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationBest Practices and Foundation Forum. Fred Wells Brason II
Best Practices and Foundation Forum Fred Wells Brason II fbrason@projectlazarus.org Wilkes County, NC Manual labor dominates employment options in this county of 69,000. Wilkes 4 Marvelous M s Moonshine
More informationOXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003
OXYCONTIN Diversion & Abuse Office of Diversion Control October 2003 OXYCONTIN OxyContin is a controlled release form of Schedule II oxycodone Manufactured in tablet form and intended for oral ingestion
More information2004-L SEPTEMBER
BULLETIN INTELLIGENCE Buprenorphine: Potential for Abuse Product No. 2004-L0424-013 SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E NDIC Within the past 2 years buprenorphine a Schedule III
More informationPrescription Opioid Dependence and Addiction: Experience in the United States
Prescription Opioid Dependence and Addiction: Experience in the United States September 27, 2013 Richard C. Dart, MD, PhD Director, Rocky Mountain Poison and Drug Center Professor, University of Colorado
More informationThe Opioid Epidemic and its Cost on Society and the Economy
The Opioid Epidemic and its Cost on Society and the Economy 6 out of 10 In 2014, more people died from drug overdoses than any other year on record with more than six out of ten deaths involving opioids.
More informationWhite Paper on. Prescription Drug Abuse
White Paper on Prescription Drug Abuse October 22, 2014 Table of Contents: I. Introduction II. Scope of the Problem III. Most Common Drugs Involved in Overdoses IV. Efforts in Tennessee V. Prescription
More informationState Action to Prevent and
State Action to Prevent and Treat Prescription Drug Abuse Paul Jarris, MD, MBA Executive Director Association of State and Territorial Health Officials Hearing from Each Other: State Reports NGA Policy
More informationInterventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?
Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference? Richard C. Dart, MD, PhD Executive Director of RADARS System, Denver, Colorado Professor, University
More informationMark W. Caverly, Chief Liaison and Policy Section
DEA Issues: An Update Harold Rogers National Prescription Drug Monitoring Meeting Meeting September 24 25, 2009 Mark W. Caverly, Chief Liaison and Policy Section Prescription Drug Abuse Prescription Drug
More informationOHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC:
Cuyahoga County Board of Health OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: NOVEMBER 5, 2014 CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements
More informationPrescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD
Prescribing Opioids in the Opioid Epidemic Scott Woffinden, PA-C Jason Chapman, JD What's the Problem? http://www.zdoggmd.com/blank-script-taylor-swift-parody/ What's the Problem? CDC 115 Americans die
More informationAHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion
Fraud and Compliance Forum, October 2017. Click here to access audio. AHLA X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Michelle Bergholz Frazier Senior Vice President,
More informationACCG Mental Health Summit
ACCG Mental Health Summit Sheila Pierce, Opioid Program Coordinator Director, Prescription Drug Management Program Discussion 1. Overview Opioid Problem in GA - Video 2. DPH Opioid Program 3. Priorities
More informationLessons Learned from the US Prescription Opioid Abuse Epidemic
Lessons Learned from the US Prescription Opioid Abuse Epidemic Michelle Lofwall, M.D. University of KY, Dept. of Psychiatry Center on Drug and Alcohol Research October 3, 2012 Outline for today s talk
More informationChanging Federal Health Care Policies
Changing Federal Health Care Policies A view from NIDA Carlos Blanco, M.D., Ph.D. Director Division of Epidemiology, Services and Prevention National Institute on Drug Abuse Advancing Addiction Science
More informationMANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling
MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN State Senator Alberta Darling A NATIONAL PROBLEM According to the 2014 National Survey on Drug Use and Health: 435,000 Americans have used heroin
More informationOur Core Thoughts on Dealing with the Opioid Addiction Crisis. Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD
Our Core Thoughts on Dealing with the Opioid Addiction Crisis Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD Outline Brief History of the Opioid Problem How did we as a medical
More informationPublic Health Federal Funding Request to Address the Opioid Epidemic
Public Health Federal Funding Request to Address the Opioid Epidemic On December 4, 2017, in response to the President s recent declaration of the opioid epidemic as a public health emergency and the final
More informationOpioid analgesic therapy in pain management: how we got here from there
National Organization of Alternative Programs March 17, 2016 Opioid analgesic therapy in pain management: how we got here from there Gary M. Reisfield, M.D. Divisions of Addiction Medicine and Forensic
More informationOregon Opioid Overdose Prevention Initiative
Oregon Opioid Overdose Prevention Initiative Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Association of Hospitals & Health Systems February 2017
More informationPrescription Opioid Policies (22 March 2016)
Prescription Opioid Policies (22 March 2016) Prescription opioid misuse and abuse has become problematic in the United States and internationally in economically developed countries. Increased use of opioids
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationGabapentin diversion and misuse: Data from law enforcement and substance users
Gabapentin diversion and misuse: Data from law enforcement and substance users Mance E. Buttram, PhD NDEWS Presents Webinar 14 March 2018 Objectives 1. Brief overview of gabapentin literature 2. Present
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationA nation in pain: Focus on Medicaid
DATA INSIGHTS A nation in pain: Focus on Medicaid Opioid pain medications have become one of the most controversial classes of prescription therapy. While they provide great benefits in controlling both
More informationResponding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team
Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Cheryl L Mejta, Ph.D. Nancy H Burley, Ed.D. Serena Wadhwa, Psy. D., LCPC, RYT, CADC Objectives Identify
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationThe Arizona Prescription Drug Reduction Initiative
The Arizona Prescription Drug Reduction Initiative A Multi-Systemic Approach for Targeting Rx Drug Misuse and Abuse Richard Rosky AZ HIDTA Program Co-Chair AZ Rx Abuse Reduction Initiative The Silent Epidemic
More informationAligning Market Objectives and Policy for National Public Health
Abuse-Deterrent Formulations Summit March 7, 2017 Alexandria, Virginia Aligning Market Objectives and Policy for National Public Health Shruti Kulkarni, Esq. Outside Counsel Twitter: @claad_coalition CLAAD
More informationHigh-Decile Prescribers: All Gain, No Pain?
High-Decile Prescribers: All Gain, No Pain? Len Paulozzi, MD, MPH National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center for Injury Prevention and
More informationAttitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.
Running Head: MEDICATION-ASSISTED TREATMENT ATTITUDES Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program Caroline Allison Dr. Kathleen Moore, Ph.D. Department of Mental Health Law
More informationMedication Misuse and Abuse: A Growing Epidemic
Medication Misuse and Abuse: A Growing Epidemic Colorado Providers Association Professionalizing Prevention June 19, 2015 Mancia Ko, PharmD, MBA Associate Director, Medical Affairs,, Ameritox Assistant
More informationSAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM
Sorin Buga, MD Associate Clinical Professor Department of Supportive Care City of Hope National Medical Center SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM Click to edit Master Presentation Date Disclosure
More informationIdentification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities
Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,
More informationApproved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina
Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures
More informationUsing Prescription Drug Monitoring Program Data to Advance Prevention Planning
September 13, 2016 Using Prescription Drug Monitoring Program Data to Advance Prevention Planning Emerging Drug Issues and Trends Chelsey Goddard, Director, SAMHSA s Center for the Application of Prevention
More informationAs part of the Opioid Analgesic REMS, all opioid analgesic companies must provide the following:
Introduction FDA s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (January 2018) Background In July 2012, FDA approved
More information